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Rotavirus  vaccine  was  introduced  in El  Salvador  in  2006  and  is recommended  to be given concomitantly
with  DTP–HepB–Haemophilus  inﬂuenzae  type  b (pentavalent)  vaccine  at ages  2 months  (upper  age  limit
15  weeks)  and  4  months  (upper  age limit 8 months)  of  age.  However,  rotavirus  vaccination  coverage
continues  to lag behind  that  of  pentavalent  vaccine,  even  in years  when  national  rotavirus  vaccine  stock-
outs  have not  occurred.  We  analyzed  factors  associated  with  receipt  of  oral  rotavirus  vaccine  among
children  who  received  at least 2 doses  of  pentavalent  vaccine  in  a  stratiﬁed  cluster  survey  of  children
aged  24–59  months  conducted  in  El  Salvador  in 2011.  Vaccine  doses  included  were  documented  on
vaccination  cards  (94.4%)  or  in health  facility  records  (5.6%).  Logistic  regression  and  survival  analysis  were
used to assess  factors  associated  with  vaccination  status  and  age  at vaccination.  Receipt  of  pentavalent
vaccine  by age  15  weeks  was  associated  with  rotavirus  vaccination  (OR: 5.1;  95% CI 2.7, 9.4),  and  receipt
of  the  second  pentavalent  dose  by  age  32  weeks  was  associated  with  receipt  of two  rotavirus  vaccine
doses  (OR:  5.0;  95%  CI 2.1–12.3).  Timely  coverage  with  the  ﬁrst  pentavalent  vaccine  dose  was  88.2%
in the  2007  cohort  and  91.1%  in  the  2008  cohort  (p =  0.04).  Children  born  in 2009,  when  a four-month
national  rotavirus  vaccine  stock-out  occurred,  had an older  median  age  of  receipt  of  rotavirus  vaccine
and  were  less  likely  to receive  rotavirus  on the  same  date  as  the  same  dose  of pentavalent  vaccine  than
children  born  in  2007  and  2008.  Upper  age limit  recommendations  for  rotavirus  vaccine  administration
contributed  to suboptimal  vaccination  coverage.  Survey  data  suggest  that  late  rotavirus  vaccination  and
co-administration  with  later  doses  of  pentavalent  vaccine  among  children  born  in  2009  helped  increase
rotavirus  vaccine  coverage  following  shortages.
ublis©  2015  The  Authors.  P
. Introduction
Diarrhea due to rotavirus is one of the leading causes of death in
hildren under 5 years of age internationally [1]. Since 2006, second
eneration live orally administered rotavirus vaccines have been
ecommended as a two-dose monovalent rotavirus vaccine (RV1;
 The ﬁndings and conclusions in this report are those of the authors and do not
ecessarily represent the views of the Centers for Disease Control and Prevention
CDC).
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Rotarix, GlaxoSmithKline Biologicals) or three-dose pentavalent
rotavirus vaccine (RV5; RotaTeq, Merck & Co., Inc.) regimen by the
World Health Organization (WHO) [1]. The El Salvador Expanded
Programme on Immunization (EPI) introduced a 2-dose oral
rotavirus vaccination series in October 2006 entirely with govern-
ment funds, as a low-middle income but non-Gavi eligible country,
and recommended administration at 2 and 4 months of age, con-
currently with injected diphtheria–tetanus–pertussis–hepatitis
B–Haemophilus inﬂuenzae type b (pentavalent) vaccine and live
oral poliovirus vaccine (OPV) [2,3]. Studies have shown a posi-
tive impact of rotavirus vaccine in El Salvador: a 2010 vaccine
effectiveness study demonstrated a four-fold reduction (OR: 0.24)
in hospitalizations for rotavirus infection among children who
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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eceived two doses of vaccine [4]; and a 2011 study found an
verall reduction in rotavirus diarrhea hospitalizations by age
roup in children under ﬁve years of age, with the most signiﬁcant
eneﬁts in birth cohorts that had been eligible for vaccination [5].
When second generation rotavirus vaccines were introduced,
he WHO  Strategic Advisory Group of Experts (SAGE) recom-
ended upper age limits of 15 weeks of age for the ﬁrst
ose and 8 months of age for completion of the two- or
hree-dose series [1,6–8]. In 2012, WHO  updated its recom-
endations supporting co-administering rotavirus vaccine with
iphtheria–tetanus–pertussis (DTP)-containing vaccine regardless
f the child’s age [1]; the same year, the Technical Advisory Group
n Vaccine-preventable Disease (TAG) of the Pan American Health
rganization (PAHO) recommended that countries of the Ameri-
as work to improve adherence to the national routine vaccination
chedule to ensure timely vaccination, with a consideration of
ossible beneﬁts of late rotavirus vaccination under some cir-
umstances [9]. Before these modiﬁed recommendations, rotavirus
accines were the only vaccines in the routine infant vaccination
chedule with upper age limits for administration [1,7]. The upper
ge limit recommendations were informed by experiences with
he ﬁrst licensed rotavirus vaccine, which was withdrawn in 1999
ecause of an increased risk of intussusception, a potentially fatal
owel obstruction caused by telescoping of one part of the intestine
nto an adjacent segment, especially among older infants [6,10,11].
ased on large safety and efﬁcacy trials and observational studies
1,6–8,12,13], the risk of intussusception following receipt of sec-
nd generation rotavirus vaccines was shown to be greatly reduced
ompared to the earlier vaccine, although continued monitoring of
his risk is still warranted.
Rotavirus vaccine is highly effective in reducing diarrheal
isease hospitalizations [4,5]. However, coverage with rotavirus
accine is often lower than that of co-administrated vaccines
2,3,14,15]. De Oliveira et al. [3] reported lower coverage with
otavirus vaccine than pentavalent vaccine in El Salvador in 2007,
008, and 2009. The authors hypothesized that the upper age lim-
ts for administration resulted in coverage discrepancies between
otavirus and pentavalent vaccines. There have been no studies
nvestigating the impact of the upper age limits on rotavirus vac-
ine coverage using data from individual children in low or middle
ncome settings in the Americas.
A national cross-sectional survey of vaccination coverage among
hildren aged 24–59 months was completed in El Salvador in
011. The primary analysis by Suarez Castaneda et al. [2] showed
otavirus vaccination coverage, estimated at 93.7% for the ﬁrst dose
nd 86.3% for the second, to be lower than coverage with the corre-
ponding doses of pentavalent vaccine, estimated at 99.9% for both
oses. Additionally, El Salvador experienced a nationwide short-
ge of rotavirus vaccine between July and October of 2009 [2]. Year
f birth was a predictor of rotavirus vaccination timeliness and the
rimary analysis of that survey concluded that further investigation
f the reasons for lower rotavirus coverage was needed [2].
We  used the dataset from the 2011 vaccination coverage sur-
ey to investigate birth cohort-speciﬁc timeliness of rotavirus and
entavalent vaccines, differences in timeliness between doses and
accines, and co-administration patterns to further understand
pper age limits and vaccine shortages as factors in lower rotavirus
accine coverage in El Salvador.
. Methods.1. Study design
The methods of the study design have been described by Suarez-
astaneda et al. [2]. Brieﬂy, this was a multi-stage stratiﬁed clusterine 33 (2015) 6865–6870
survey of all ﬁve regions of El Salvador, conducted from 1 November
to 2 December 2011. Thirty clusters were sampled via probabil-
ity proportional to size from each of the 5 regions. Seventeen
households within each locality were selected (details described
in [2]), and one eligible child was randomly selected in each house-
hold, yielding a sample size of 2550 2- to 4-year-old children born
between 4 November 2006 and 12 December 2009. Caregivers were
interviewed about their child’s vaccination status and their atti-
tudes toward vaccination. Vaccination dates were obtained from
children’s vaccination cards at home (94.4%) or at health facilities
if the card was unavailable (5.6%). The survey based coverage esti-
mates on the 2006 national vaccination schedule for children less
than two  years of age. Only two children had no written record of
vaccination and were excluded; both had received vaccines accord-
ing to parental report. For each missing dose of vaccine, the parent
or guardian was  asked to recall the reason it was not administered.
Parents or guardians were also surveyed about family and commu-
nity characteristics, such as parental education level and marital
status, number of people in the household, levels of community
violence (e.g., gang activity), and accessibility of vaccination clinics.
These self-reported factors were recorded for each child.
2.2. Analytic methods
The current analysis is limited to the sample of children born in
2007–2009 with at least 2 documented doses of pentavalent vac-
cine (N = 2492); children born in 2006 (n = 55) and children who
had not received at least 2 doses of pentavalent vaccine (n = 3)
were excluded. To reﬂect national policy and facilitate compar-
isons between the doses, schedule adherence for both vaccines was
categorized using the recommended upper age limits for rotavirus
vaccine of 104 days for the ﬁrst dose and 223 days for the ﬁnal
dose of the series. Percentages and (Wald) conﬁdence intervals
were calculated accounting for the survey design and the weights
provide by the original authors using SAS v9.3 (Cary, NC). These
are reported for deﬁned sub-populations overall, and by birth
year. The weighted median ages of administration of rotavirus and
pentavalent vaccines are presented with absolute ranges. Logistic
regression models, also accounting for survey design and weights,
were developed for rotavirus vaccination status predicted by the
timing of the corresponding dose of pentavalent vaccine, that is
administered before or after the upper age limit for rotavirus
vaccination, and year of birth; categorical pentavalent timeliness
(doses administered within 30 days of the recommended age) was
predicted by year of birth. Confounding was assessed using the
backwards change in estimate approach [16].
In the time-to-event analysis, children were considered eligi-
ble for each dose of vaccine from birth. Children without a written
record of the vaccine of interest were censored at their age at
the time of the survey. For the second dose of vaccine, children
were considered vaccinated if they had a written record for the
ﬁrst and second doses. The results are presented in graphs plot-
ting one minus the proportion of unvaccinated children by age in
months. These images were generated using R (3.0) survey method
survival analysis package to account for the sample weights and
survey design.
The survey was  reviewed by the national and PAHO ethical com-
mittees and considered non-research. This secondary analysis was
approved by Emory University’s Institutional Review Board and the
Centers for Disease Control and Prevention.3. Results
Table 1 describes the characteristics of the surveyed children
and their households. Of 2495 children included in El Salvador’s
E. Suarez-Castaneda et al. / Vaccine 33 (2015) 6865–6870 6867
Table  1
Selected characteristics of surveyed children born 2007–2009 with at least 2 documented doses of pentavalent vaccine, their families and communities. El Salvador, 2011.
Year of birth
2007 (N = 806) 2008 (N = 877) 2009 (N = 809)
n % n % n %
Gender Female 387 48.0 428 48.8 383 47.3
Parental marital status Partnered/married 652 80.9 702 80.1 650 80.4
Divorced/separated 22 2.7 24 2.7 17 2.1
Single 124 15.4 143 16.3 135 16.7
Widowed 8 1.0 8 0.9 7 0.9
Parental education level Less than 7th grade 442 54.8 482 55.0 481 59.5
7th  grade or higher 364 45.2 395 45.0 328 40.5
Parental employment status Not employed 572 71.1 602 68.6 564 69.7
Outside the home 234 29.0 275 31.4 245 30.3
Number of people in the household 2–5 503 62.4 564 64.3 503 62.2
6  or more 303 37.6 313 35.7 306 37.8
Primary mode of transportation Foot 439 54.5 462 52.7 391 48.3
Bus  243 30.2 275 31.4 299 37.0
Personal vehicle 53 6.6 64 7.3 61 7.5
Other 71 8.8 76 8.7 58 7.2
Area  of residence Urban area 363 45.0 443 50.5 361 44.6
Presence of organized crime Yes 131 16.3 143 16.3 142 17.6
Region Central 154 19.1 184 21.0 162 20.0
Metropolitan 152 18.9 179 20.4 158 19.5
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011 national vaccination coverage survey born during 2007–2009,
492 (99.8%) had received at least two doses of pentavalent vac-
ine. Among these, 2338 (93.8%) of 2492 had documentation of
eceipt of the ﬁrst dose of oral rotavirus vaccine and 2162 (86.3%)
ad completed the two-dose rotavirus vaccination series. Median
ge at receipt of ﬁrst dose of pentavalent vaccine (penta1) was  62.4
ays (range: 0–1234 days) and median age at receipt of the sec-
nd dose (penta2) was 125.3 days (range: 58–1398 days), close
o the recommended ages of 2 and 4 months, respectively. Simi-
arly, oral rotavirus vaccine doses were received at a median age of
3.7 days (range: 0–1183 days) for the ﬁrst dose (rota1) and 126.8
ays (Range: 58–1463 days) for the second dose (rota2). Among
338 children who received the ﬁrst dose of rotavirus vaccine, 1814
77.2%) received rota1 and penta1 on the same date, and 453 (19.9%)
eceived rota1 a median of 55.2 days after penta1 (Table 2). Among
162 children who received the second dose of rotavirus vaccine,
613 (74.8%) received rota2 and penta2 on the same date, while 429
19.9%) received rota2 a median of 40.9 days after penta2. Among
hildren who received rota1 on a different date than penta1 and
enta2, 99.1% received OPV1 on the same day as penta1; among
hildren who received rota2 on a different date than penta2 and
enta3, 96.8% received OPV2 on the same day as penta2.
able 2
oncurrent administration of rotavirus and pentavalenta vaccines among children born in
Year of birt
Total 2007 (N = 8
n % CI n % 
Rotavirus dose 1
(N = 2338)
With penta1b 1814 77.2 (75.0, 79.4) 592 80
With  penta2c 166 7.4 (6.1, 8.6) 50 7
In  a separate visit 358 15.4 (13.7, 17.2) 90 12
Rotavirus dose 2
(N = 2162)
With penta2 1613 74.8 (72.8, 76.9) 542 77
With  penta3d 95 4.8 (3.7, 5.9) 20 2
In  a separate visit 454 20.4 (18.6, 22.2) 138 19
a Diphtheria–tetanus–pertussis–Hepatitis B–Haemophilus inﬂuenzae type b vaccine.
b Penta1 is the ﬁrst dose of pentavalent vaccine.
c Penta2 is the second dose of pentavalent vaccine.
d Penta2 is the second dose of pentavalent vaccine.21.0 175 20.0 155 19.2
20.0 181 20.6 160 19.8
21.1 158 18.0 174 21.5
Delayed receipt of pentavalent vaccine was strongly associ-
ated with non-receipt of rotavirus vaccine or incomplete rotavirus
vaccination. Among 154 children with zero doses of rotavirus vac-
cine despite having received two  doses of pentavalent vaccine, 29
(19.7%) had received the ﬁrst pentavalent vaccine after 15 weeks
of age. Among 176 children with only one dose of rotavirus vac-
cine, 12 (7.3%) had received penta2 after 32 weeks of age. After
adjusting for year of birth and maternal education, odds of receipt
of oral rotavirus vaccine were lower among children who  received
penta1 after 15 weeks of age compared with those who received
penta1 before 15 weeks of age (OR: 0.2; 95% CI 0.1, 0.4) (Table 3).
Among children who  received rota1, odds of receipt of rota2 were
lower among those who  received penta2 after 32 weeks of age
compared with those who  received the vaccine before 32 weeks
(OR: 0.1; 95% CI 0.1, 0.2). Urban residence, maternal employment
status, and number of residents in the household were not found
to be confounders. Uptake of rotavirus vaccine in children who
received pentavalent vaccine before and after the upper age limits
of administration are visualized using cumulative incidence curves
(Fig. 1).
In  the ﬁrst two  birth cohorts to receive oral rotavirus vac-
cine before national shortages in 2009, we observed signiﬁcant
 2007–2009. El Salvador, 2011.
h
06) 2008 (N = 877) 2009 (N = 809)
CI n % CI n % CI
.6 (77.5, 83.7) 701 84.4 (81.8, 87.0) 521 66.4 (62.2, 70.7)
.2 (5.1, 9.2) 34 4.1 (2.6, 5.7) 83 11.0 (8.5, 13.5)
.3 (9.5, 15.1) 97 11.4 (9.2, 13.7) 171 22.6 (19.0, 26.1)
.9 (74.6, 81.3) 610 80.9 (77.5, 84.2) 461 66.5 (61.6, 69.4)
.9 (1.6, 4.3) 19 2.4 (1.3, 3.6) 56 9.1 (6.2, 12.0)
.1 (16.0, 22.3) 125 16.7 (13.6, 19.8) 191 25.4 (22.0, 28.9)
6868 E. Suarez-Castaneda et al. / Vaccine 33 (2015) 6865–6870
Table  3
Odds ratios of receiving rotavirus vaccine by pentavalent timing and birth cohort among children born 2007–2009 who received a dose of pentavalent vaccine. El Salvador,
2011.
Rotavirus dose 1 Rotavirus dose 2
Administered Crude Adjusteda Administered Crude Adjustedb
n % (CI) n % (CI)
Pentavalent before
age limit
2236 94.7 (93.3, 96.1) 1.0 (reference) 1.0 (reference) 2129 87.7 (85.7, 89.7) 1.0 (reference) 1.0 (reference)
Pentavalent after
age limit
102 78.3 (69.3, 87.4) 0.2 (0.1, 0.4) 0.2 (0.1, 0.4) 85 64.1 (54.0, 74.1) 0.1 (0.1, 0.2) 0.1 (0.1, 0.2)
Born  in 2007 732 90.6 (88.2, 93.1) 1.0 (reference) 1.0 (reference) 700 86.4 (83.5, 89.4) 1.0 (reference) 1.0 (reference)
Born  in 2008 832 94.8 (92.9, 97.8) 1.9 (1.3, 2.8) 1.9 (1.2, 2.6) 754 85.2 (82.0, 88.4) 0.9 (0.7, 1.2) 0.8 (0.6, 1.1)
Born  in 2009 774 95.7 (94.1, 97.3) 2.3 (1.6, 3.4) 2.3 (1.5, 3.3) 708 87.4 (84.5, 90.2) 1.1 (0.8, 1.4) 1.0 (0.7, 1.3)
Less  than 7th grade
education
1323 93.9 (92.3, 95.5) 0.9 (0.7, 1.3) 1.1 (0.7, 1.4) 933 85.0 (81.9, 88.1) 1.2 (0.9, 1.6) 1.1 (0.9, 1.5)
7th  grade
education or
higher
1015 93.5 (91.6, 95.6) 1.0 (reference) 1.0 (reference) 1229 87.3 (84.9, 89.6) 1.0 (reference) 1.0 (reference)
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b Adjusted for pentavalent dose 2 categorical timeliness, parental education and 
mprovement in timeliness of pentavalent vaccination among chil-
ren included in the survey. The percentage of children who  had
eceived a valid dose of penta1 by 3 months (90 days) of age
ncreased from 88.2% in the 2007 cohort to 91.1% in the 2008 cohort
p = 0.04), although there was little difference in the median age of
enta1: 62.5 compared with 62.3 days. Controlling for maternal
ig. 1. Cumulative incidence curves showing the probability of rotavirus vaccination for
otavirus vaccine administration, El Salvador, 2011.
he probability of rotavirus vaccination is shown with solid lines and conﬁdence interval
he  ﬁrst dose of rotavirus vaccine, among children who received the ﬁrst dose of pentaval
n  the left column and after the upper age limit in the right column. The bottom row show
hildren who  received the second dose of pentavalent vaccine before the series rotaviru
ge  limit in the right column. The gray boxes highlight the minimum acceptable age untiohort.
ohort.
education, odds of penta1 receipt by 3 months of age were 1.6-fold
higher among children born in 2008 compared with those born in
2007 (OR: 1.6; 95% CI 1.1, 2.3). The percentage of children who had
received penta2 by 5 months of age was 84.6% in the 2007 cohort
compared to 87.4% among those born in 2008 (p = 0.10); odds of
timely vaccination was  not statistically different (OR: 1.1; 95% CI:
 children who received pentavalent vaccine before and after the upper age limit of
s are shown as dotted lines. The top row shows the probability of vaccination with
ent vaccine before the ﬁrst dose rotavirus vaccine upper age limit (15 weeks of age)
s the probability of vaccination with the second dose of rotavirus vaccine, among
s vaccine upper age limit (8 months of age) in the left column and after the upper
l 30 days after the recommended age for the rotavirus dose.
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.8, 1.6) after controlling for maternal education, penta1 timeli-
ess, urban residence, maternal employment status, and number
f residents in the household.
Despite nationwide shortages of rotavirus vaccine from July to
ctober, 2009, 95.7% (95% CI: 94.1, 97.3) of children born in 2009
eceived rota1 and 87.4% (95% CI: 84.5, 90.2) received rota2, simi-
ar to percentages of children born in 2007 (90.6% and 86.4%) and
008 (94.8% and 85.2%, respectively). However, the median age of
eceipt of penta2 was 124.7 days in 2008 compared with 125.9 in
009, and 22.1% of children born in 2009 received rota1 after 15
eeks of age compared with 9.0% in 2008. Compared with children
n the 2007 and 2008 birth cohorts, children born in 2009 were
ore likely to have received rota2 with the third dose of pentava-
ent vaccine (penta3) or on separate dates from penta2 and penta3
2007/2008: 20.6%, 2009: 34.5%; p: 0.001) (Table 2). The primary
eason parents gave for their children not receiving rotavirus vac-
ine was that there was no rotavirus vaccine at the time of their
isit, with 63.2, 72.1, and 89.4% of parents citing this reason in the
007, 2008, and 2009 birth cohort, respectively.
The number of surveyed children who received rota1 in
ovember 2009, the month following the nationwide shortage was
34, higher than the number of children aged 2–3 months (n = 80)
nd exceeding the number of rota1 doses received in any other
onth children in the study were vaccinated with the ﬁrst dose of
otavirus vaccine. The increase in rota1 doses received in November
009 was followed by an increased number of rota2 doses received
n January 2010.
. Discussion
This analysis suggests that shortages of vaccine and missed
pportunities led to suboptimal rotavirus vaccine coverage dur-
ng the ﬁrst three years following rotavirus vaccine introduction
n El Salvador’s national immunization program, though ﬁrst dose
otavirus vaccine coverage was improving by birth cohort. High
overage and timeliness of other routine vaccinations indicate the
verall strength of the program at the time of rotavirus vaccine
ntroduction; adherence to upper age limits during the ﬁrst two
ears also indicates well-trained vaccination staff. This analysis also
howed an increased proportion of infants receiving both doses of
otavirus vaccine after the recommended ages in the 2009 birth
ohort, suggesting efforts to provide rotavirus vaccine to infants
ligible for vaccination during vaccine shortages. When forecast-
ng vaccination coverage after new vaccine introduction, it is often
ssumed that a newly introduced vaccine will quickly achieve the
ame coverage level as established vaccines recommended at the
ame ages [3] and previous publications have hypothesized that the
ecommended upper age limits for rotavirus vaccine are related to
ower coverage [1,6,14]. This analysis showed that age-speciﬁc rec-
mmendations contributed to lower coverage, though to a lesser
xtent than missed opportunities and vaccine shortages. Other
ariables associated with delayed pentavalent or rotavirus vacci-
ation included child’s year of birth and gender, vaccination in
he private sector, and mother’s education and marital status [2].
ur ﬁndings support the revised recommendations from WHO  and
AHO advisory bodies to consider the beneﬁts and risks of rotavirus
accination among older infants, while still working to improve
chedule adherence.
This analysis also showed that the timeliness of the ﬁrst dose
f pentavalent vaccine increased signiﬁcantly as the rotavirus
accine program matured during the ﬁrst two years after introduc-
ion, before national vaccine shortages. Previous studies found an
ssociation between rotavirus vaccine introduction and improved
imeliness of other vaccines [15,17] and that new vaccine introduc-
ion can strengthen service delivery in existing routine vaccinationine 33 (2015) 6865–6870 6869
programs [18]. As this survey did not include cohorts born before
and after rotavirus vaccine introduction, we were unable to assess
improved timeliness in administration for other routine infant vac-
cines as observed in Australia [17] and Paraguay (unpublished data
2011).
Our results also highlight challenges of new vaccine intro-
duction, including the implications of shortages on vaccination
coverage and timely administration [3,19–21]. The results of this
survey show that the immunization program in El Salvador was
ﬂexible in its handling of the national rotavirus vaccine shortages,
resulting in a minimal reduction in rotavirus vaccination coverage
in 2009 but delayed administration. This was evidenced through
adaptability in co-administration and diligent follow-up of chil-
dren who  had not received rotavirus vaccine, or who  were partially
vaccinated, in the months following the national stock-out. Other
subnational shortages likely played a role in lower and less timely
coverage with rotavirus vaccine during the study period, as sug-
gested by the reasons parents provided for not having received
rotavirus vaccine even before 2009.
This study had several limitations. Because the survey did not
include cohorts before the rotavirus vaccine was  introduced, we
were unable to draw conclusions about the association between
rotavirus vaccine introduction and the timeliness of routine infant
vaccinations. The 2009 national vaccine shortage also limited our
ability to look at improvements in timeliness across birth cohorts.
Although the unavailability of the vaccine was identiﬁed as a pri-
mary reason for non-vaccination [2], we were unable to verify
information about local vaccination stock or consider provider atti-
tudes toward vaccinations and contraindications to vaccination for
individual children.
This study also has several strengths. The analysis included three
birth cohorts of children eligible for rotavirus and pentavalent vac-
cines with complete documentation of the dates of administration.
As receiving pentavalent vaccine was  nearly universal, it is clear
that there is access to immunization services in this strong program.
In addition, because the vaccination and community and family
factor data were individually linked, we were able to assess associ-
ations based on individual information, rather than ecological and
aggregated data. Finally, the overall sample size was  sufﬁciently
large to allow us to produce estimates by birth cohort.
Our ﬁndings add to the limited literature about the use and
coverage of rotavirus vaccine, with a restricted period for valid
administration and its impact on timing and coverage. The experi-
ence with rotavirus vaccine introduction in El Salvador is unique,
but it can provide potentially helpful information for other country
programs considering introducing this and other new vaccines, as
well as promoting the use of existing survey data to answer spe-
ciﬁc questions regarding newer vaccines. The ﬁndings of this study
also add to the growing number of analyses looking at vaccination
timeliness and adherence to recommended ages for administration
in low and middle income countries [2,22,23] and follows PAHO’s
new guidance tool for secondary survey analyses created in col-
laboration with the US Centers for Disease Control and Prevention
[24]. El Salvador and other countries that have or will soon intro-
duce new vaccines should continue to carefully monitor availability
of vaccine, vaccination coverage, and timeliness and simultaneity
of vaccine administration. Vaccination programs should encourage
administration of all recommended vaccines during vaccination
visits to avoid missed opportunities and rapidly accelerate coverage
of new vaccines.Acknowledgements
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